معرفی
Anders Bjartell is a distinguished Professor and Principal Investigator at Lund University, holding multiple leadership positions including Manager of Urological Cancer Research in Malmö, Professor in the eSSENCE: The e-Science Collaboration, and Professor in EpiHealth: Epidemiology for Health. He serves as a Principal Investigator at the Lund University Cancer Centre (LUCC), where he directs significant research initiatives in prostate cancer.
Dr. Bjartell's research focuses on translational prostate cancer studies, with particular emphasis on identifying molecular targets for therapies in chemo- and hormone-resistant prostate cancer. His work spans in vitro studies, animal models, biomarker development and validation in tissue, blood and urine (including circulating tumor cells), biobanking, and clinical studies on imaging biomarkers and robotic surgery. His fingerprint analysis reveals strong activity in Prostate Cancer (100%), Patient care (61%), Prostatectomy (29%), Therapeutic Procedures (23%), and Man-related studies (23%), with significant contributions to Prostate-Specific Antigen research (16%), Robot-Assisted Prostatectomy (12%), and Biological Markers (11%).
The recent publication trends in Dr. Bjartell's work demonstrate a strategic shift toward integrating artificial intelligence with traditional prostate cancer research, particularly in digital pathology, imaging analysis, and risk stratification. His involvement in major international collaborations like the PIONEER big data platform shows commitment to leveraging real-world evidence for advancing prostate cancer care. The research spans from basic molecular investigations to large-scale clinical implementation studies, reflecting a comprehensive translational approach.
- EAU Frans Debruyne Life Time Achievement Award (2025)
- Referenced in multiple patents and Wikipedia pages
- Extensive scholarly impact with over 370 research outputs
Dr. Bjartell has supervised 16 research projects and students, demonstrating strong mentorship capacity. His current projects include 'Biomarkers and targeted therapies for advanced prostate cancer' (2024-2028), 'Digital Optimisation of Gleason Scoring (DOGS)', and development of new imaging biomarkers for PET/CT. He actively organizes academic events including the LUCC - Malmö Cancer Seminars (March 2024), LUCC - UroCAN conferences, and AI-focused cancer research seminars, establishing himself as a central figure in the prostate cancer research community.
His laboratory infrastructure supports comprehensive prostate cancer research from molecular analysis through clinical implementation, with particular strengths in biomarker validation, digital pathology, and integration of AI technologies into prostate cancer diagnostics and management.
